PER 2.47% 8.3¢ percheron therapeutics limited

VALIDATION OF THE ANTISENSE DRUG. Schmidt believes, “Ionis...

  1. 12,627 Posts.
    lightbulb Created with Sketch. 1272
    VALIDATION OF THE ANTISENSE DRUG.

    Schmidt believes, “Ionis Pharmaceuticals has validated its antisense platform by successfully shepherding systemic antisense drugs to commercial feasibility. We believe antisense candidates have the best chance of success when directed at treating orphan diseases that lack treatment alternatives. Prime examples within Ionis’s pipeline include candidates for spinal muscular atrophy (SMA), TTR amyloidosis, and familial chylomicronemia syndrome (FCS).”
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.3¢
Change
0.002(2.47%)
Mkt cap ! $74.82M
Open High Low Value Volume
9.0¢ 9.0¢ 8.2¢ $9.57K 112.6K

Buyers (Bids)

No. Vol. Price($)
2 124862 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.9¢ 11000 1
View Market Depth
Last trade - 15.56pm 29/03/2024 (20 minute delay) ?
Last
8.2¢
  Change
0.002 ( 0.86 %)
Open High Low Volume
8.2¢ 8.3¢ 8.2¢ 31700
Last updated 15.55pm 29/03/2024 ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.